Comparative Pharmacology
Head-to-head clinical analysis: ADALAT versus KATERZIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT versus KATERZIA.
ADALAT vs KATERZIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
KATERZIA (bosentan) is an endothelin receptor antagonist (ERA) that blocks endothelin-1 (ET-1) from binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. This inhibits ET-1-mediated vasoconstriction and smooth muscle proliferation, reducing pulmonary vascular resistance and pulmonary arterial pressure.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
5 mg orally once daily for 21 days, then 7 days off, repeated in 28-day cycles.
None Documented
None Documented
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Terminal elimination half-life is approximately 9-12 hours in healthy adults. In patients with hypertension or hepatic impairment, half-life may be prolonged up to 15-20 hours, necessitating dose adjustment.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Renal elimination accounts for approximately 60-80% of the administered dose, predominantly as unchanged drug via glomerular filtration and active tubular secretion. Biliary/fecal excretion is minimal, <5%.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker